文献速递冠心病

急性心肌梗死中的炎症:好的、坏的和丑的

Inflammation in acute myocardial infarction: the good, the bad and the ugly.
PubMed 文献 · Eur Heart J · 2024-01-01

综述指出,促炎通路在冠心病中具有病理生理重要性,AMl后炎症治疗兴趣从慢性扩展到急性期。大型结局试验证实靶向残余炎症风险(RIR)的抗炎治疗可改善心血管结局,但存在宿主防御受损风险;近期小型试验针对AMI早期过度炎症爆发,干预IL-1和IL-6通路取得不同程度成功。提出优化策略:选择高促炎负荷(大面积AMI)患者、早期(如≤12小时)启动、精准靶向抗炎药、逐渐减量方案,需严格临床试验验证。

要点

  • 大型试验证实靶向RIR的抗炎治疗改善心血管结局,但需警惕宿主防御受损。
  • 早期干预IL-1和IL-6通路的小型试验显示不同程度成功。
  • 优化策略:选大面积AMI、≤12小时启动、精准抗炎、逐渐减量。

核心结论

  • 靶向AMI后炎症需区分有益修复防御、有害残余炎症风险和急性期过度炎症爆发,优化策略需严格临床试验验证。

研究设计与样本

  • 综述汇总实验与临床证据,涵盖大型结局试验和多项小型试验,评估抗炎治疗对心血管结局的影响。

主要发现

  • 大型结局试验证实靶向残余炎症风险的抗炎治疗可改善心血管结局,但存在宿主防御受损风险。
  • 小型试验针对AMI早期过度炎症,干预IL-1和IL-6通路取得不同程度成功。

关键数值与推荐

  • 选择高促炎负荷患者(即大面积AMI);早期启动治疗(如AMI后≤12小时);使用精准靶向抗炎药;采用逐渐减量方案。

临床怎么用

  • 临床可考虑对大面积AMI患者早期(≤12小时)启动精准抗炎治疗并逐渐减量,但需严格试验验证。

局限性

  • 大型结局试验主要针对慢性期残余炎症风险,早期干预证据多来自小型试验,优化策略尚未在严格临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare 'The Good' (repair and defence) while treating 'The Bad' (smouldering RIR) and capturing 'The Ugly' (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Matter, Paneni, Libby, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024. PMID: 37587550. doi:10.1093/eurheartj/ehad486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。